

CORRECTION

Open Access



# Correction: Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial

Jessica Ailani<sup>1</sup>, Peter McAllister<sup>2</sup>, Paul K. Winner<sup>3</sup>, George Chakhava<sup>4</sup>, Mette Krog Josiassen<sup>5</sup>, Annika Lindsten<sup>5</sup>, Bjørn Sperling<sup>5</sup>, Anders Ettrup<sup>5</sup> and Roger Cady<sup>6,7\*</sup>

**Correction:** *BMC Neurol* 22, 205 (2022)  
<https://doi.org/10.1186/s12883-022-02714-1>

Following publication of the original article [1], the authors identified an error in Figs. 1 and 2. The correct figures are given below.

The original article [1] has been updated.

---

The original article can be found online at <https://doi.org/10.1186/s12883-022-02714-1>.

\*Correspondence:

Roger Cady  
[rcady@rkconsults.com](mailto:rcady@rkconsults.com)

<sup>1</sup> Department of Neurology, Georgetown University Hospital, Washington, DC, USA

<sup>2</sup> New England Institute for Neurology and Headache, Stamford, CT, USA

<sup>3</sup> Palm Beach Headache Center, West Palm Beach, FL, USA

<sup>4</sup> Georgian Association of Medical Specialties, Multiprofile Clinic Consilium Medulla, D.Tvildiani Medical University, Tbilisi, Georgia


<sup>5</sup> H. Lundbeck A/S, Copenhagen, Denmark

<sup>6</sup> Lundbeck LLC, Deerfield, IL, USA


<sup>7</sup> RK Consults, Ozark, MO, USA



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.



**Fig. 1** Time Course to Headache Pain Freedom (A), Headache Pain Relief (B), and Absence of MBS (C). \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$  vs placebo in analysis censoring for use of rescue medication. The teal/gray bars represent the percentage of patients achieving headache pain freedom (A), headache pain relief (B), and absence of MBS (C) without rescue medication use prior to the achievement. The white bars represent the percent of patients achieving headache pain freedom (A), headache pain relief (B), and absence of MBS (C) regardless of rescue medication use



**Fig. 2** Time Course to Absence of Photophobia (A), Phonophobia (B), and Nausea (C). \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$  vs placebo in analysis censoring for use of rescue medication. Analyses were conducted in patients experiencing the corresponding symptom with their qualifying migraine. The teal/gray bars represent the percentage of patients achieving absence of photophobia (A), phonophobia (B), and nausea (C) without rescue medication use prior to the achievement. The white bars represent the percent of patients achieving absence of photophobia (A), phonophobia (B), and nausea (C) regardless of rescue medication use

Published online: 06 September 2023

**Reference**

1. Ailani J, McAllister P, Winner PK, et al. Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial. BMC Neurol. 2022;22:205. <https://doi.org/10.1186/s12883-022-02714-1>.